Recombinant Adeno-Associated Virus Delivery of Alpha-Sarcoglycan Polynucleotides

ABSTRACT

The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.

This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 61/563,139 filed Nov. 23, 2011, which is incorporated by reference herein in its entirety.

STATEMENT OF GOVERNMENT INTEREST

This invention was made with government support under Grant No. 5U54NS055958-03 awarded by the United States National Institute of Health/National Institute of Neurological Disorders and Stroke. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.

INCORPORATION BY REFERENCE OF THE SEQUENCE LISTING

This application contains, as a separate part of disclosure, a Sequence Listing in computer-readable form (filename: 45210PCT_SeqListing.txt; 23,573 byte—ASCII text file) which is incorporated by reference herein in its entirety.

BACKGROUND

Muscular dystrophies (MDs) are a group of genetic diseases. The group is characterized by progressive weakness and degeneration of the skeletal muscles that control movement. Some forms of MD develop in infancy or childhood, while others may not appear until middle age or later. The disorders differ in terms of the distribution and extent of muscle weakness (some forms of MD also affect cardiac muscle), the age of onset, the rate of progression, and the pattern of inheritance.

One group of MDs is the limb girdle group (LGMD) of MDs. LGMDs are rare conditions and they present differently in different people with respect to age of onset, areas of muscle weakness, heart and respiratory involvement, rate of progression and severity. LGMDs can begin in childhood, adolescence, young adulthood or even later. Both genders are affected equally. LGMDs cause weakness in the shoulder and pelvic girdle, with nearby muscles in the upper legs and arms sometimes also weakening with time. Weakness of the legs often appears before that of the arms. Facial muscles are usually unaffected. As the condition progresses, people can have problems with walking and may need to use a wheelchair over time. The involvement of shoulder and arm muscles can lead to difficulty in raising arms over head and in lifting objects. In some types of LGMD, the heart and breathing muscles may be involved.

There are at least nineteen forms of LGMD, and the forms are classified by their associated genetic defects.

Type Pattern of Inheritance Gene or Chromosome LGMD1A Autosomal dominant Myotilin gene LGMD1B Autosomal dominant Lamin A/C gene LGMD1C Autosomal dominant Caveolin gene LGMD1D Autosomal dominant Chromosome 7 LGMD1E Autosomal dominant Chromosome 6 LGMD1F Autosomal dominant Chromosome 7 LGMD1G Autosomal dominant Chromosome 4 LGMD2A Autosomal recessive Calpain-3 gene LGMD2B Autosomal recessive Dysferlin gene LGMD2C Autosomal recessive Gamma-sarcoglycan gene LGMD2D Autosomal recessive Alpha-sarcoglycan gene LGMD2E Autosomal recessive Beta-sarcoglycan gene LGMD2F Autosomal recessive Delta-sarcoglycan gene LGMD2G Autosomal recessive Telethonin gene LGMD2H Autosomal recessive TRIM32 LGMD2I Autosomal recessive FKRP gene LGMD2J Autosomal recessive Titin gene LGMD2K Autosomal recessive POMT1 gene LGMD2L Autosomal recessive Fukutin gene

Specialized tests for LGMD are now available through a national scheme for diagnosis, the National Commissioning Group (NCG).

U.S. Pat. No. 6,262,035 states it discloses a method for treating a patient suffering from the disease sarcoglycan-deficient limb-girdle muscular dystrophy by gene replacement therapy. It claims intramuscular injection of an expression vector containing alpha-sarcoglycan nucleic acid. See also, Allamand et al., Gene Ther., 7(16): 1385-1391 (2000).

The present inventors delivered an alpha-sarcoglycan gene in an adeno-associated type 1 vector by intramuscular injection with the goal of treating LGMD2D as described in Rodino-Klapac et al., Neurology, 71: 240-247 (2008); Mendell et al., Ann. Neurol., 66(3): 290-297 (2009); and Mendell et al., Ann. Neurol., 68(5): 629-638 (2010).

Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including 145 nucleotide inverted terminal repeat (ITRs). There are multiple serotypes of AAV. The nucleotide sequences of the genomes of the AAV serotypes are known. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and Srivastava et al., J. Virol., 45: 555-564 {1983); the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the AAV-5 genome is provided in GenBank Accession No. AF085716; the complete genome of AAV-6 is provided in GenBank Accession No. NC_00 1862; at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively (see also U.S. Pat. Nos. 7,282,199 and 7,790,449 relating to AAV-8); the AAV-9 genome is provided in Gao et al., J. Virol., 78: 6381-6388 (2004); the AAV-10 genome is provided in Mol. Ther., 13(1): 67-76 (2006); and the AAV-11 genome is provided in Virology, 330(2): 375-383 (2004). Cis-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the AAV ITRs. Three AAV promoters (named p5, p19, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes. The two rep promoters (p5 and p19), coupled with the differential splicing of the single AAV intron (at nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome. The cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology, 158: 97-129 (1992).

AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells allowing the possibility of targeting many different tissues in vivo. Moreover, AAV transduces slowly dividing and non-dividing cells, and can persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in plasmids which makes construction of recombinant genomes feasible. Furthermore, because the signals directing AAV replication, genome encapsidation and integration are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA. The rep and cap proteins may be provided in trans. Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56° to 65° C. for several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.

The present inventors have used an AAV8-like AAV termed rh.74 to deliver DNAs encoding various proteins. Xu et al., Neuromuscular Disorders, 17: 209-220 (2007) and Martin et al., Am. J. Physiol. Cell. Physiol., 296: 476-488 (2009) relate to rh.74 expression of cytotoxic T cell GalNAc transferase for Duchenne muscular dystrophy. Rodino-Klapac et al., Mol. Ther., 18(1): 109-117 (2010) describes AAV rh.74 expression of a micro-dystrophin FLAG protein tag fusion after delivery of the AAV rh.74 by vascular limb perfusion.

The muscular dystrophies are a group of diseases without identifiable treatment that gravely impact individuals, families, and communities. The costs are incalculable. Individuals suffer emotional strain and reduced quality of life associated with loss of self-esteem. Extreme physical challenges resulting from loss of limb function creates hardships in activities of daily living. Family dynamics suffer through financial loss and challenges to interpersonal relationships. Siblings of the affected feel estranged, and strife between spouses often leads to divorce, especially if responsibility for the muscular dystrophy can be laid at the feet of one of the parental partners. The burden of quest to find a cure often becomes a life-long, highly focused effort that detracts and challenges every aspect of life. Beyond the family, the community bears a financial burden through the need for added facilities to accommodate the handicaps of the muscular dystrophy population in special education, special transportation, and costs for recurrent hospitalizations to treat recurrent respiratory tract infections and cardiac complications. Financial responsibilities are shared by state and federal governmental agencies extending the responsibilities to the taxpaying community.

There thus remains a need in the art for treatments for muscular dystrophies including limb girdle muscular dystrophies such as LGMD2D.

DESCRIPTION

The present invention provides methods and products for preventing, delaying the progression of, and/or treating limb girdle muscular dystrophies. The methods involve vascular delivery (e.g., by limb perfusion including, but not limited to, re-circulating methodology) of an alpha-sarcoglycan expression cassette to muscle cells using AAV as a gene delivery vector. For example, the alpha sarcoglycan expression cassette is inserted in the genome of the AAV referred to as AAV rh.74 herein.

In one aspect, the invention provides an AAV referred to as AAV rh.74. AAV rh.74 exhibits about 93% identity to AAV8 capsid. FIG. 1 provides an alignment of the AAV rh.74 capsid amino acid sequence with the AAV8 capsid amino acid sequence. The polynucleotide and amino acid sequences of the AAV rh.74 capsid are respectively set out in SEQ ID NOs: 1 and 2.

In another aspect, a method of ameliorating limb girdle muscular dystrophy type 2D (LGMD) in a patient is provided. In some embodiments, the method comprises the step of perfusing the vasculature of a limb of the patient with a rAAV comprising the AAV rh.74 capsid of SEQ ID NO: 2 and comprising an alpha-sarcoglycan polynucleotide (for example, the polynucleotide of SEQ ID NO: 3) in a gene expression cassette in the virus genome.

In yet another aspect, the invention provides a method of inhibiting the progression of dystrophic pathology associated with LGMD 2D. In some embodiments, the method comprises the step of perfusing the vasculature of a limb of the patient with a rAAV comprising AAV rh.74 capsid of SEQ ID NO: 2 and comprising an alpha-sarcoglycan polynucleotide (for example, the polynucleotide of SEQ ID NO: 3) in a gene expression cassette in the virus genome.

In still another aspect, a method of improving muscle function in a patient afflicted with limb girdle muscular dystrophy type 2D (LGMD 2D) is provided. In some embodiments, the method comprises the step of perfusing the vasculature of a limb of the patient with a rAAV comprising AAV rh.74 capsid of SEQ ID NO: 2 and comprising an alpha-sarcoglycan polynucleotide (for example, the polynucleotide of SEQ ID NO: 3) in a gene expression cassette in the virus genome. In some instances, the improvement in muscle function is an improvement in muscle strength. The improvement in muscle strength is determined by techniques known in the art such as the maximal voluntary isometric contraction testing (MVICT). In some instances, the improvement in muscle function is an improvement in stability in standing and walking. The improvement in stability strength is determined by techniques known in the art such as the 6-minute walk test (6MWT) or timed stair climb.

In another aspect, the invention provides a method of delivering an alpha-sarcoglycan polynucleotide to an animal (including, but not limited to, a human). In some embodiments, the method comprises the step of perfusing the vasculature of a limb of the animal with a rAAV comprising the AAV rh.74 capsid of SEQ ID NO: 2 and comprising an alpha sarcoglycan polynucleotide (for example, the polynucleotide of SEQ ID NO: 3) in a gene expression cassette in the virus genome.

Cell transduction efficiencies of the methods of the invention described above and below may be at least about 60, 65, 70, 75, 80, 85, 90 or 95 percent. In some embodiments, transduction efficiency is increased by increasing the volume of the composition in which the rAAV is delivered, pre-flushing before delivery of the rAAV and/or increasing dwell time of the rAAV.

In some embodiments of the foregoing methods of the invention, the virus genome is a self-complementary genome. In some embodiments of the methods, the genome of the rAAV lacks AAV rep and cap DNA. In some embodiments of the methods, the rAAV is AAVrh.74.tMCK.hSGCA

In yet another aspect, the invention provides a rAAV comprising the AAV rh.74 capsid of SEQ ID NO: 2 and comprising an alpha sarcoglycan polynucleotide (for example, the polynucleotide of SEQ ID NO: 3) in a gene expression cassette in the virus genome. In some embodiments, the genome of the rAAV lacks AAV rep and cap DNA. In some embodiments, the rAAV is a self-complementary genome. In some embodiments, the rAAV is AAVrh.74.tMCK.hSGCA

Recombinant AAV genomes of the invention comprise one or more AAV ITRs flanking a polynucleotide encoding alpha sarcoglycan. The polynucleotide is operatively linked to transcriptional control DNA, specifically promoter and polyadenylation signal DNAs that are functional in target, forming an expression cassette. AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10 and AAV-11. As noted in the Background section above, the nucleotide sequences of the genomes of various AAV serotypes are known in the art. In some embodiments of the invention, the promoter DNAs are muscle-specific control elements, including, but not limited to, those derived from the actin and myosin gene families, such as from the myoD gene family [See Weintraub et al., Science, 251: 761-766 (1991)], the myocyte-specific enhancer binding factor MEF-2 [Cserjesi and Olson, Mol. Cell. Biol., 11: 4854-4862 (1991)], control elements derived from the human skeletal actin gene [Muscat et al., Mol. Cell. Biol., 7: 4089-4099 (1987)], the cardiac actin gene, muscle creatine kinase sequence elements [Johnson et al., Mol. Cell. Biol., 9:3393-3399 (1989)] and the murine creatine kinase enhancer (MCK) element, desmin promoter, control elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene: hypozia-inducible nuclear factors [Semenza et al., Proc. Natl. Acad. Sci. USA, 88: 5680-5684 (1991)], steroid-inducible elements and promoters including the glucocorticoid response element (GRE) [See Mader and White, Proc. Natl. Acad. Sci. USA, 90: 5603-5607 (1993)], and other control elements.

DNA plasmids of the invention comprise rAAV genomes of the invention. The DNA plasmids are transferred to cells permissible for infection with a helper virus of AAV (e.g., adenovirus, E1-deleted adenovirus or herpesvirus) for assembly of the rAAV genome into infectious viral particles. Techniques to produce rAAV particles, in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to a cell are standard in the art. Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from (i.e., not in) the rAAV genome, and helper virus functions. The AAV rep genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10 and AAV-11. Use of cognate components is specifically contemplated. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 which is incorporated by reference herein in its entirety.

A method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell. AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of synthetic linkers containing restriction endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65-73) or by direct, blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV. Other examples of suitable methods employ adenovirus or baculovirus rather than plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells.

General principles of rAAV production are reviewed in, for example, Carter, 1992, Current Opinions in Biotechnology, 1533-539; and Muzyczka, 1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Various approaches are described in Ratschin et al., Mol. Cell. Biol. 4:2072 (1984); Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984); Tratschin et al., Mo1. Cell. Biol. 5:3251 (1985); McLaughlin et al., J. Virol., 62:1963 (1988); and Lebkowski et al., 1988 Mol. Cell. Biol., 7:349 (1988). Samulski et al. (1989, J. Virol., 63:3822-3828); U.S. Pat. No. 5,173,414; WO 95/13365 and corresponding U.S. Pat. No. 5,658,776; WO 95/13392; WO 96/17947; PCT/US98/18600; WO 97/09441 (PCT/US96/14423); WO 97/08298 (PCT/US96/13872); WO 97/21825 (PCT/US96/20777); WO 97/06243 (PCT/FR96/01064); WO 99/11764; Perrin et al. (1995) Vaccine 13:1244-1250; Paul et al. (1993) Human Gene Therapy 4:609-615; Clark et al. (1996) Gene Therapy 3:1124-1132; U.S. Pat. Nos. 5,786,211; 5,871,982; and 6,258,595. The foregoing documents are hereby incorporated by reference in their entirety herein, with particular emphasis on those sections of the documents relating to rAAV production.

The invention thus provides packaging cells that produce infectious rAAV. In one embodiment packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line). In another embodiment, packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with E1 of adenovirus), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).

The rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for example, Clark et al., Hum. Gene Ther., 10(6): 1031-1039 (1999); Schenpp and Clark, Methods Mol. Med., 69 427-443 (2002); U.S. Pat. No. 6,566,118 and WO 98/09657.

In another embodiment, the invention contemplates compositions comprising rAAV of the present invention. Compositions of the invention comprise rAAV in a pharmaceutically acceptable carrier. The compositions may also comprise other ingredients such as diluents. Acceptable carriers and diluents are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, pluronics or polyethylene glycol (PEG).

Titers of rAAV to be administered in methods of the invention will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art. Titers of rAAV may range from about 1×10⁶, about 1×10⁷, about 1×10⁸, about 1×10⁹, about 1×10¹⁰, about 1×10¹¹, about 1×10¹², about 1×10¹³ to about 1×10¹⁴ or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg) (i.e., 1×10⁷ vg, 1×10⁸ vg, 1×10⁹ vg, 1×10¹⁰ vg, 1×10¹¹ vg, 1×10¹² vg, 1×10¹³ vg, 1×10¹⁴ vg, respectively).

Methods of transducing a target cell (e.g., a skeletal muscle, smooth muscle or cardiac muscle cell) with rAAV, in vivo or in vitro, are contemplated by the invention. The methods comprise the step of administering an effective dose, or effective multiple doses, of a composition comprising a rAAV of the invention to an animal (including a human being) in need thereof. If the dose is administered prior to development of a LGMD2D, the administration is prophylactic. If the dose is administered after the development of LGMD2D, the administration is therapeutic. In embodiments of the invention, an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with LGMD2D being treated, that slows or prevents progression to LGMD2D, that slows or prevents progression of a disorder/disease state, that diminishes the extent of disease, that results in remission (partial or total) of disease, and/or that prolongs survival.

Combination therapies are also contemplated by the invention. Combination as used herein includes simultaneous treatment or sequential treatments. Combinations of methods of the invention with standard medical treatments (e.g., corticosteroids and/or immunosuppressive drugs) are specifically contemplated, as are combinations with novel therapies.

Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.

The composition comprising a rAAV of the invention may also be administered to an animal (including a human being) in need thereof using a system such as is illustrated in FIG. 5, and/or according to a method such as illustrated in FIG. 6. In this regard, FIGS. 7 and 8 may have been simplified by the omission of selected elements for the purpose of more clearly showing other elements. Such omissions of elements in some figures are not necessarily indicative of the presence or absence of particular elements in any of the exemplary embodiments, except as may be explicitly delineated in the corresponding written description. FIG. 5 is not necessarily to scale.

FIG. 5 illustrates an exemplary system 100 that may be used according to the present disclosure to deliver the rAAV, potentially in combination with other treatments and therapies, according to an isolated whole limb recirculation protocol. The system 100 includes a venous catheter 102, a pump 104, an optional oxygenator 106, an optional heat exchanger 108 (which may according to certain embodiments be formed integrally with the oxygenator 106), and an arterial catheter 110. In addition, the system 100 may include a one or more sets defining a circuit 120 connecting the venous catheter 102 to the arterial catheter 110, and received within or connected to the pump 104, the oxygenator 106, and the heat exchanger 108. These sets may include one or more connectors, which may be luer-type connectors, as well as tubing and reservoirs.

In fact, according to one embodiment of the present circuit 120, the circuit 120 may include a first connection (and collection) site 122 and a second connection (and introduction) site 124. Either or both of the connection sites 122, 124 may be defined by a luer connector incorporating a stopcock, permitting fluid to be diverted from the circuit 120. For example, the first connection site 122 may include first and second luer connectors, each with a stopcock and attached line. The second connection site 124 may include a single stopcock with attached line. The lines running between the catheters 102, 110, the other equipment (pump 104, optional oxygenator 106, optional heat exchanger 108) and the sites 122, 124 may be exaggerated in FIG. 5 for ease of illustration.

As illustrated, the venous catheter 102 is connected to a first end of the circuit 120 that is received in the pump 104, which may be a peristaltic or roller pump according to certain embodiments. The circuit 120 may also be connected to the oxygenator 106 if the perfusate passing through the circuit 120 is blood, for example. If fluids other than blood are passed through the circuit 120 between the catheters 102, 110, then the oxygenator 106 may not be required. Additionally, the circuit 120 may be received or connected to a heat exchanger 108, which heat exchanger 108 may be used to control or maintain the temperature of the fluid passing through the circuit 120. As noted above, the heat exchanger 108 is presently believed to be optional, and may not be included in all embodiments of the present disclosure. The circuit 120 is connected at a second end to the arterial catheter 110.

The system 100 may be connected to a patient 150, and in particular, to a limb 152 (e.g., lower extremity) of the patient 150 that has been isolated from the remainder of the patient's body 154 by a tight or tightly-placed tourniquet 156, which is provided as an exemplary isolation device or system. The venous catheter 102 may be placed or disposed within a vein 160 (e.g., femoral vein) of the limb 152, while the arterial catheter 110 may be placed or disposed within an artery 162 (e.g., femoral artery) of the limb 152. As illustrated, the insertion site of the venous catheter 102 and the insertion site of the arterial catheter 110 are adjacent each other and only slightly distal of the tourniquet 156.

Where the limb 152 is the lower extremity (i.e., a leg), both catheter sites may be in the groin region. However, according to other embodiments, the venous catheter 102 may be disposed only slightly distal to the tourniquet 156, while the arterial catheter 110 is disposed at a considerable distance from the tourniquet 156. For example, where the limb 152 is a leg, one site may be in the groin, and the other at the ankle. According to still other embodiments, an upper extremity (i.e., an arm) may be targeted.

The catheters 102, 110 may be introduced into the vein and artery, respectively, either by surgical cut down and blunt dissection or by less invasive procedures, such as the Seldinger technique (percutaneously). In regard to the later technique, it may be possible to introduce the catheters at a location remote to the limb undergoing perfusion and to advance the catheters from the remote site to a location proximate to the limb to be perfused. In fact, balloon catheters may be used to perform both the connection to the circuit 120 and (when inflated) the isolation of the limb from the remainder the patient's body.

The system 100 is operated to circulate a fluid, which may be referred to as the perfusate, from the point of insertion of the arterial catheter 110 through the limb 152 to the point of insertion of the venous catheter 110, through the pump 104, optional oxygenator 106, and optional heat exchanger 108, and back to the arterial catheter 110. As noted above, certain embodiments may employ the patient's blood, potentially in combination with additional blood or blood components. However, according to certain embodiments of the present disclosure, the perfusate may be saline or a buffer solution. According to a non-blood perfusate embodiment, the blood may be removed from the limb 152 via the venous catheter 102 (and the site 122), while the perfusate is introduced via the arterial catheter 110 (and the site 124).

The system 100 may also include sensors that may be used to monitor the flow of the perfusate through the system 100 and the limb 152, and may even be used to control the operation of the pump 104, for example. In particular, pressure sensors 170, 172 may be disposed upstream (venous side) and downstream (arterial side) of the pump 104 and optional oxygenator 106 and heat exchanger 108. In particular, the sensor 170 may be used to determine if a low pressure condition is occurring on upstream of the pump 104 such that the operation of the pump 104 should be stopped momentarily to prevent damage to the blood vessels of the limb 152.

A method 200 of operating the system 100 is illustrated in FIG. 6 to deliver an rAAV. It will be understood that the method 200 may be carried out using equipment other than that illustrated in FIG. 5 (i.e., system 100). In addition, it will be understood that the system 100 may be used to carry out a method other than the method 200 illustrated in FIG. 6. However, according to certain embodiments, the system 100 may be operated in accordance with the method 200.

The method 200 begins at block 202 with the insertion of the catheters 102, 110, or at least with the insertion of the venous catheter 102 into the vein 160. At block 202, the circuit 120 may also be connected to the catheters 102, 110 (and thereby to the vasculature of the limb 152). Method 200 continues at block 204 with the isolation of the limb 152 from the remainder 154 of the body, which may be achieved by applying the tourniquet 156 to the limb 152 for example. It will be recognized that the order of the steps of blocks 202 and 204 may in fact be reversed according to certain embodiments of the present method. Depending on the choice of perfusate, the method 200 may then proceed to optional block 206.

If the perfusate is other than blood (i.e., a non-blood perfusate), then at block 206 a volume of the patient's blood is removed from the limb 152 via the venous catheter 102 and the site 122 while the non-blood perfusate (e.g., a buffer solution, such as Normosol-R available from Hospira Inc., Lake Forest, Ill.) is introduced into the circuit 120 and the limb 152 via the site 124 and the arterial catheter 110. The blood may be disposed in a sterile blood bag, and an anti-coagulant may be added to the blood, such as ACD-A or Heparin, for storage. The volume of blood would then be stored using conventional methods for later reintroduction, as explained in detail below.

Alternatively, the patient's own blood may be used as the perfusate. However, if the patient's own blood is used, then it may be advisable to provide for oxygenation of the blood by way of the optional oxygenator 106. Moreover, it may also be advisable to screen the blood for antibodies and complements that have specific binding sites for the rAAV, or that exhibit non-specific biding with the rAAV. If the patient is naïve to the rAAV, no further action may be required. However, if the patient has antibodies or complements that exhibit specific or non-specific binding with the rAAV, the blood may need to be filtered before it is used as the perfusate in the method 200. For example, plasmapheresis may be used to remove the antibodies and/or complements from the patient's blood.

In either event, some additional perfusate may be added to facilitate the travel of the rAAV within the limb 152, and in particular within the muscles of the limb 152. However, because vascular pressures that are excessive are believed to be detrimental to the tissue of the limb 152, overall volume of perfusate used is minimized according to certain embodiments of the present disclosure.

Once the step of block 206 has been performed, if required, the pump 104 is activated to cause the perfusate to circulate through the limb 152 to perfuse limb 152 at block 208. According to certain embodiments of the present disclosure, after perfusion of the limb 152 has begun, the rAAV may be administered at block 210 through its introduction (injection) into the circuit 120 and the limb 152, for example via the arterial catheter 110. According to other embodiments, the administration of the rAAV may occur prior to the activation of the pump 104 or may be delayed some period of time after the perfusion has begun. The rAAV is then permitted to recirculate, or pass repeatedly, with the perfusate through the circuit 120 and limb 152 for a period of time at block 212.

The period of time that the perfusate and rAAV is recirculating may be varied from patient to patient, and between treatments of the same patient. For example, the time period may be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes. For that matter, the time period may be at least 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes or 1 hour. According to certain embodiments, the time period may even exceed 3 hours, although many treatments may be less than 2 hours in length. According to particular embodiments, the time period may be approximately or about 30 minutes.

Once the recirculation of the perfusate and rAAV has been conducted over the desired time period, the perfusate and any rAAV remaining in the perfusate may be removed from the circuit 120 and the limb 152 at block 214. While it may be possible to perform a flush of the limb 152 by introducing a perfusate without rAAV as the perfusate with residual rAAV is removed, it is not expected that such a flush will be routinely performed. It also may be possible to reintroduce or reperfuse the limb 152 at this point with the volume of the patient's blood removed from the limb 152 at the beginning of the procedure, although this also may not occur according to all embodiments of the present method 200.

Once the perfusate has been replaced with the blood at block 214 (if desired), the isolation of the limb 152 may be discontinued, by removing the tourniquet 156 for example, at block 216. At this point or immediately prior to block 216, the catheters 102, 110 may be removed from the vein 160 and artery 162 of the limb 152 at block 218, thereby disconnecting the circuit 120 from the limb 152.

It is believed that the use of a recirculating system, such as the system 100, and a method of recirculation, such as the method 200, may have one or more advantages with regard to the administration of the rAAV. To begin, the recirculation thus described facilitates the travel of the rAAV to all or nearly all regions of the limb 152, and in particular to all or nearly all of the muscle fibers of the muscles of the limb 152, and for those regions to be exposed to the rAAV multiple times. Both the widespread nature of the exposure, as well as the duration/frequency of the exposure, are believed to assist in the rAAV transferring the genetic material into the muscle cells and the interstitial spaces between the muscle fiber cells of the targeted limb 152. However, further advantages may be obtained when a non-oxygenated perfusate is used in the system 100 and the limb 152. It will be recognized that if a non-oxygenated perfusate (e.g., a buffer solution) is used in the system 100 and limb 152, the tissue of the limb will experience hypoxia and/or acidosis over time because of the lack of oxygen in the circulating perfusate. Hypoxia and acidosis are known to cause blood vessels to dilate (vasodilatation). As a consequence, it is believed that the travel of the perfusate and the rAAV carried by the perfusate will be further facilitated because of the dilated nature of the vessels, permitting the perfusate and rAAV to travel deep within the tissues of the targeted limb 152.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 is an alignment of the AAV rh.74 (SEQ ID NO: 2) and AAV8 capsid (SEQ ID NO: 4) amino acid sequences.

FIG. 2 shows the tMCK-aSG gene cassette.

FIG. 3 shows the sc.tMCk.aSG vector plasmid.

FIG. 4 is the rh74 genome sequence (SEQ ID NO: 5) wherein nucleotides 210-2147 are the Rep 78 gene open reading frame, 882-208 are the Rep52 open reading frame, 2079-2081 are the Rep78 stop, 2145-2147 are the Rep78 stop, 1797-1800 are a splice donor site, 2094-2097 are a splice acceptor site, 2121-2124 are a splice acceptor site, 174-181 are the p5 promoter+1 predicted, 145-151 are the p5 TATA box, 758-761 are the p19 promoter+1 predicted, 732-738 are the p19 TATA box, 1711-1716 are the p40 TATA box, 2098-4314 are the VP1 Cap gene open reading frame, 2509-2511 are the VP2 start, 2707-2709 are the VP3 start and 4328-4333 are a polyA signal.

FIG. 5 is a schematic illustration of a system for recirculating the rAAV according to the present disclosure.

FIG. 6 is a flowchart of a method of recirculating rAAV according to the present disclosure.

FIG. 7 shows the average transgene expression throughout the lower extremity following vascular delivery and recirculation of 6×10¹² vg/kg of rAAV comprising an enhanced green fluorescent protein (eGFP) transgene, AAVrh.74.CMD.eGFP. A) Each representative panel is a direct fluorescent image of a section of muscle demonstrating the extent of eGFP expression. The Biceps (a non-targeted muscle from the upper extremity is presented as a negative control). B) Each bar represents an average of two muscles-one from each lower extremity of a Rhesus macaque and shows the percent muscle fiber transgene expression of the major lower extremity muscles. QVL=Vastus Lateralis, QRF=Rectus Femoris, QVM=Vastus Medialis, QVI=Vastus Intermedius, HBF=Biceps Femoris, HSM=Semimembranosus, HST=Semitendinosus, HSart=Sartorius, HGrac=Gracilis, GlutMax=Gluteus Max, GlutMed=Gluteus Med, TA=Tibialis Anterior, EDL=Extensor Digitorum Longus, MG=Medial Gastrocnemius, LG=Lateral Gastrocnemius, Sol=Soleus.

FIG. 8 shows the average transgene expression throughout the lower extremity following vascular delivery and recirculation of 2×10¹² vg/kg of vector (AAVrh.74.CMD.eGFP). A) Each representative panel is a direct fluorescent image of a section of muscle demonstrating the extent of transgene expression. The Biceps (a non-targeted muscle from the upper extremity is presented as a negative control). B) Each bar represents an average of two muscles-one from each lower extremity of a Rhesus macaque and shows the percent muscle fiber transgene expression of the major lower extremity muscles. QVL=Vastus Lateralis, QRF=Rectus Femoris, QVM=Vastus Medialis, QVI=Vastus Intermedius, HBF=Biceps Femoris, HSM=Semimembranosus, HST=Semitendinosus, HSart=Sartorius, HGrac=Gracilis, GlutMax=Gluteus Max, GlutMed=Gluteus Med, TA=Tibialis Anterior, EDL=Extensor Digitorum Longus, MG=Medial Gastrocnemius, LG=Lateral Gastrocnemius, Sol=Soleus.

FIG. 9 shows the average transgene expression throughout the lower extremity following vascular delivery and recirculation of 6×10¹² vg/kg of AAVrh.74.MCK.micro-dystrophin. A) Each representative panel is an immunofluorescent image of a section of muscle demonstrating the extent of transgene expression. The Biceps (a non-targeted muscle from the upper extremity is presented as a negative control). B) Each bar represents an average of two muscles-one from each lower extremity of a Rhesus macaque and shows the percent muscle fiber transgene expression of the major lower extremity muscles. QVL=Vastus Lateralis, QRF=Rectus Femoris, QVM=Vastus Medialis, QVI=Vastus Intermedius, HBF=Biceps Femoris, HSM=Semimembranosus, HST=Semitendinosus, HSart=Sartorius, HGrac=Gracilis, GlutMax=Gluteus Max, GlutMed=Gluteus Med, LCF=Lateral Caudal Femoris, TA=Tibialis Anterior, EDL=Extensor Digitorum Longus, MG=Medial Gastrocnemius, LG=Lateral Gastrocnemius, Sol=Soleus.

FIG. 10 shows the average transgene expression throughout the lower extremity following vascular delivery and recirculation of 6×10¹² vg/kg of AAVrh.74.tMCK.SGCA. A) Each representative panel is an immunofluorescent image of a section of muscle demonstrating the extent of transgene expression. The Biceps (a non-targeted muscle from the upper extremity is presented as a negative control). B) Each bar represents the average of two muscles-one from each lower extremity of a Rhesus macaque and shows the percent muscle fiber transgene expression of the major lower extremity muscles. QVL=Vastus Lateralis, QRF=Rectus Femoris, QVM=Vastus Medialis, QVI=Vastus Intermedius, HBF=Biceps Femoris, HSM=Semimembranosus, HST=Semitendinosus, HSart=Sartorius, HGrac=Gracilis, GlutMax=Gluteus Max, GlutMed=Gluteus Med, LCF=Lateral Caudal Femoris, TA=Tibialis Anterior, EDL=Extensor Digitorum Longus, MG=Medial Gastrocnemius, LG=Lateral Gastrocnemius, Sol=Soleus.

FIG. 11 shows rAAV.rh.74.tMCK.SGCA gene transfer restores specific force and resistance to eccentric contractions in the EDL of alpha-sarcoglycan knock-out mice. Alpha-sarcoglycan knock-out mice (n=12 per group) were treated by ILP at high (2×10¹² vg/kg) and low (6×10¹¹ vg/kg) doses.

EXAMPLES

Thus, aspects and embodiments of the invention are illustrated by the following examples. Example 1 describes the isolation of AAV rh.74. Example 2 describes alpha-sarcoglycan gene expression from a highly active expression cassette combined with a self-complementary AAV vector. Example 3 describes gene delivery via the mouse vasculature using AAV rh.74. Example 4 describes the vascular delivery of AAVrh.74.tMCK.hSGCA in non-human primates. Example 5 describes the biodistribution of the AAVrh.74.tMCK.hSGCA vector in the macaques. Example 6 describes administration of AAVrh.74.tMCK.hSGCA to a human patient. Example 7 describes isolated whole limb re-circulation (IWRLC) methodology according to the invention. Example 8 describes IWLRC in the non-human primate with a reporter construct. Example 9 describes IWLRC in the non-human primate with therapeutic transgenes. Example 10 describes vascular delivery of SC rAAV8.tMCK.hSGCA to alpha-sarcoglycan knock-out mice.

Example 1 Isolation of AAV rh.74

A unique AAV serotype was isolated from a rhesus macaque lymph node using a novel technique termed Linear Rolling Circle Amplification. Using the LRCA process, double-stranded circular AAV genomes were amplified from several rhesus macaques. The method is predicated on the ability to amplify circular AAV genomes by isothermic rolling circle amplification using phi29 phage DNA polymerase and AAV specific primers. LRCA products are contiguous head-to-tail arrays of the circular AAV genomes from which full-length AAV Rep-Cap molecular clones were isolated. Four isolates were sequenced and the predicted amino acid sequences for Rep and Cap ORFs were aligned and compared to previously published serotypes (Table). VP1 protein sequences were analyzed and revealed homology to the NHP AAV clades D, E, and AAV 4-like virus isolates. Analysis of the Rep78 (top portion of Table) ORF revealed strong homology to AAV 1 (98-99%).

TABLE 1 AAV 1 AAV 4 AAV 7 AAV 8 rh.73 rh.74 rh.75 rh.76 AAV 1 — 90 98 95 98 98 99 AAV 4 63 — 90 87 90 90 90 AAV 7 85 63 — 96 97 98 98 AAV 8 84 63 88 — 97 97 95 rh.73 79 61 83 80 — 99 99 rh.74 84 63 88 93 80 — 99 rh.75 65 82 82 64 62 64 — rh.76 85 63 91 86 84 86 84 Similarity of published AAV sequences and the new AAV sequences determined using one-pair alignment according to the Lipman-Pearson method implemented in the MegAlgn software in DNASTAR (DNASTAR Inc.) Light faced numbers (top, right) represent similarity in Rep78 sequences, whereas bold-faced numbers (lower, left) represent similarity in VP1 capsid sequences.

One macaque tissue sample (rh426-M) yielded a divergent AAV8-like isolate termed rh.74 that shares 93% sequence identity with AAV8. The nucleotide and amino acid sequences of the rh.74 capsid gene are respectively set out in SEQ ID NOs: 1 and 2. FIG. 1 shows an alignment of the rh.74 (SEQ ID NO: 2) and the AAV8 capsid (SEQ ID NO: 4) amino acid sequences.

The rh.74 capsid gene sequence was cloned into an AAV helper plasmid containing the Rep gene from AAV2 to provide vector replication functions for recombinant AAV vector production.

Example 2 Robust Alpha-Sarcoglycan Gene Expression Using a Highly Active Expression Cassette Combined with a Self-Complementary AAV Vector

A vector was designed with several features to maximize the opportunity for clinical success. First, to ameliorate possible immune responses to the vector expression cassette, a synthetic codon-optimized human alpha-sarcoglycan cDNA (hSCGA) was placed under the control of a muscle specific promoter (the truncated muscle creatine kinase promoter/enhancer). The tMCK promoter was a gift from Dr. Xiao Xiao (University of North Carolina). It is a modification of the previously described CK6 promoter [Shield et al., Mol Cell Biol, 16:5058-5068 (1996)] and includes a modification in the enhancer upstream of the promoter region containing transcription factor binding sites. The enhancer is composed of two E-boxes (right and left). The tMCK promoter modification includes a mutation converting the left E-box to a right E-box (2R modification) and a 6 bp insertion (S5 modification). The nucleotide sequence of the hSCGA is set out in SEQ ID NO: 3. Second, the construct also includes a chimeric intron to promote high level expression. The chimeric intron is composed of the 5′ donor site from the first intron of the human β-globin gene and the branchpoint and 3′ splice acceptor site from the intron that is between the leader and the body of an immunoglobulin gene heavy chain variable region. Third, a synthetic SV40 polyadenylation signal is used for efficient transcription termination. A schematic of the expression cassette is shown below in FIG. 2.

The expression cassette was inserted into the pHpa7 self-complementary AAV vector plasmid backbone to generate plasmid sc.tMCK.aSG shown in FIG. 3. The location of the expression cassette elements in the plasmid is given in Table 2 below.

TABLE 2 Type Start End Name Description REGION 1 116 ITR Inverted terminal repeat REGION 147 860 tMCKp Truncated MCK promoter REGION 891 1024 sd/sa Chimeric intron GENE 1064 2228 ha-SG Human alpha sarcoglycan gene REGION 2229 2280 pA SV40 late polyadenylation signal REGION 2377 2480 ITR Inverted terminal repeat

To maximize vector potency and reduce the dosing requirements, a self-complementary (SC) AAV vector was produced. SC AAV vectors demonstrate increased gene expression and express the protein product sooner than standard single-stranded AAV vectors. This improvement is achieved by deleting a small portion of one AAV inverted terminal repeat (ITR) that causes AAV replication to proceed to a dimeric replication intermediate that is then packaged into AAV particles.

The recombinant SC AAV vector (AAVrh.74.tMCK.hSGCA) expressing the alpha-sarcoglycan gene from the muscle specific tMCK promoter was produced by a modified cross-packaging approach using the plasmid sc.tMCK.aSG in an adenovirus-free, triple plasmid DNA transfection (CaPO₄ precipitation) method in HEK293 cells [Rabinowitz et al., J. Virol., 76:791-801 (2002)]. Vector was produced by co-transfecting with an AAV helper plasmid rep2-cap rh.74 and an adenovirus helper plasmid in similar fashion as that previously described [Wang et al., Gene. Ther., 10:1528-1534 (2003)]. Plasmid rep2-cap rh.74 encodes the wild-type AAV2 rep gene and rh.74 cap gene, and the adenovirus helper plasmid (pAdhelper) expresses the adenovirus type 5 E2A, E40RF6, and VA I/II RNA genes which are required for high-titer rAAV production.

Vectors were purified from clarified 293 cell lysates by sequential iodixanol gradient purification and anion-exchange column chromatography using a linear NaCl salt gradient as previously described [Clark et al., Hum. Gene Ther, 10:1031-1039 (1999)]. Vector genome (vg) titers were measured using QPCR based detection with a tMCK specific primer/probe set and utilized the Prism 7500 Taqman detector system (PE Applied Biosystems) as previously described (Clark et al., supra). Vector stock titers ranged between 1-10×10¹² vg/mL.

Example 3 Efficient Gene Delivery Via the Mouse Vasculature Using AAV Rh.74

With respect to clinical application, rather than delivering alpha-sarcoglycan gene by direct injection into the muscle, meaningful results will be best attained using a gene transfer approach that has the ability to reach widespread muscle targets resulting in an improvement in the patient's quality of life. A vascular delivery approach allows for a one-time vector infusion to reach multiple muscles instead of direct injections that would be necessary using a direct injection intramuscular approach. Moreover, benefits of a regional vascular approach include: lack of widespread dissemination of virus; safe passage of the virus directly to the targeted muscles; and transduction of multiple muscles in, for example, the leg.

AAVrh.74 Micro-Dystrophin Gene Delivery Versus AAV1 and AAV6 Delivery

The AAV1 serotype transduces muscle efficiently by direct intramuscular injection, however comparative studies demonstrated that AAVrh.74 delivered through the circulation is vastly superior to AAV1 and superior to AAV6 in transducing skeletal muscle via this route. As described in Rodino-Klapac et al., J. of Transl. Med, 5: 45 (2007), AAV6 and AAV rh.74 carrying a micro-dystrophin gene demonstrated ease in crossing the vascular barrier when delivered to skeletal muscle in the mdx mouse through a catheter in the femoral artery. Extremely efficient regional vascular delivery was observed using AAVrh.74.micro-dystrophin, and yielded percent transduced myofibers as follows: 94.5±0.9 (1 month), 91.3±3.1 (2 months), and 89.6±1.6% (3 months). AAV6.micro-dystrophin treated animals demonstrated 87.7±6.8 (1 month), 78.9±7.4 (2 months), and 81.2±6.2% (3 months) transduction. In striking contrast, AAV1 demonstrated very low transduction efficiency [0.9±0.3 (1 month), 2.1±0.8 (2 months), and 2.1±0.7% (3 months)] by the vascular delivery route. The delivery of micro-dystrophin through the femoral artery was accompanied by functional improvement as measured by protection against contraction-induced injury and improvement in tetanic force.

AAVrh.74.tMCK.hSGCA Vascular Delivery in Knock-Out Mice

In the present experiments, the AAVrh.74.tMCK.hSGCA was delivered by isolated limb perfusion to the alpha-sarcoglycan knock-out mouse.

Sedated and anesthetized animals secured to a surgical platform were prepared and draped in the usual sterile fashion. Suture-tourniquets (3.0 braided silk) were placed loosely around the thigh near the inguinal region. A small incision was placed over the femoral bundle visible through the skin. The femoral artery was isolated and cannulated with a heat-pulled polyethylene (PE) 10 catheter prefilled with normal saline and secured in place. The tourniquet was tightened and a pre-flush of normal saline was delivered. Following the pre-flush, the vector dose 2×10¹² vg/kg wt was administered and allowed to dwell for 10 minutes. After the 10-minute dwell a final post-flush of normal saline was delivered, and the catheter and tourniquet removed and the animal recovered.

Three-months post-gene transfer, transduction levels were observed averaging 78.2±11% of muscle fibers. Not only was the transgene appropriately expressed at the muscle fiber periphery in greater than 75% of muscle fibers, muscle function (measured as specific force) was restored in treated animal muscles compared to non-treated muscle. In other experiments, gene transfer of up to 90% positive fibers in the lower extremity musculature was observed.

Example 4 AAVrh.74.tMCK.hSGCA Vascular Delivery in Non-Human Primates

The above success in the mouse promulgated extensive studies in non-human primates using both cynomologus and rhesus macaques. In both species, a clinically relevant, intra-arterial delivery system was used.

Sedated and anesthetized animals were secured to a surgical bed. Proximal and distal tourniquets were loosely positioned above the knee and below the gastrocemius muscle of a macaque. A small incision was placed at the femoral triangle and the femoral artery was identified and dissected free and looped with proximal and distal ligatures to control bleeding and facilitate catheter introduction. The femoral artery was cannulated with a 3.0 Fr introducer sheath via a modified Seldinger method by passing the pre-flushed sheath over a wire previously placed in the artery. The sheath was advanced only a few centimeters and secured in place with a 3.0 braided silk suture.

Heparinization was achieved with 50 U/kg body weight via the sheath and the sheath was cleared with normal saline. Fluoroscopy was used to generate a road map of the vasculature by administering a few milliliters of contrast agent through the sheath and capturing the fluoroscopic image. A 3.0 Fr, 50 cm long catheter was placed into the introducer sheath and advanced a few centimeters. A guide wire (0.018 in., diameter) was placed through the catheter and, under fluoroscopic guidance, advanced to the sural arteries, which perfuse the two heads of the gastrocnemius. Once the catheter was correctly positioned, the vascular bed of the gastrocnemius was isolated by the placement of proximal and distal tourniquets. The proximal tourniquet was placed above the knee and just proximal to the catheter tip. Optimal placement of the proximal tourniquet was assessed by partial tourniquet tightening and visualization of a small volume (few milliliters) of injected contrast agent Once the relationship of the proximal tourniquet to catheter tip was established, the contrast was flushed from the limb with normal saline and the distal tourniquet was positioned just below the gastrocnemius. The second tourniquet provides compartmentalization of the gastrocnemius. Dosing began with a pre-flush volume (2.5 mL/kg) of normal saline delivered over 60 sec. with the tourniquets pulled snug. While the final volume was administered, the tourniquets were pulled tight to occlude blood flow. With the tourniquets pulled tight the rAAV vector carrying the gene of interest, AAVrh.74.tMCK.hSGCA (2×10¹² viral genomes per kg in 2.5 mL per kg volume), was administered over 60 s. Allow 10 min. dwell time with the tourniquets left tight. Following the 10 min dwell and with the tourniquets still tight and occluding blood flow, a post-volume of normal saline (2.5 mL/kg) was administered over 60 s. At the completion of dosing the tourniquets and catheter were removed and direct pressure was applied to the wound for 10 min to control bleeding. The wound was closed with a continuous subcuticular 4.0 Vicryl suture. A pressure dressing was applied to the site and kept in place until the animal awoke from anesthesia.

Following the above vector delivery protocol, similarly treated animals were sacrificed 12 to 24 weeks later and muscle samples were removed for storage and study. Gene expression was measured by antibody staining of the transgene expression product in situ.

Muscle transduction exceeded 75% in the muscles of interest using doses applicable to a clinical trial. Evaluation of antibody stained microscopic images of the treated muscles showed that micro-dystrophin, alpha-sarcoglycan or a FLAG-tag (6 amino acid tag attached to the transgene) was expressed at the fiber periphery, the region known as the sarcolemma. This is the region of normal expression for these proteins. Muscles not targeted had very low levels of transgene expression highlighting the specific nature of the targeting. Robust expression in other animals treated was observed for up to six months.

Example 5 AAVrh.74 Vector Biodistribution

By using the femoral artery delivery approach described in Example 4, vector escape outside the limb was minimized as shown by PCR-based detection of AAV vector genomes in organs throughout the body at the time of animal necropsy. FIG. 6 shows vector biodistribution data from fifteen monkeys receiving vector through the femoral artery. Only the targeted muscle (gastrocnemius) and spleen shows significant number of vector genomes. These samples were obtained three weeks post-gene delivery through the femoral artery. The number of vector genomes recovered from remote sites were negligible (note the log scale).

Example 6 Dose Escalation Study

A dose escalation study of AAVrh74.tMCK.hSGCA delivered via the femoral artery to the quadriceps muscles of both legs of LGMD2D (alpha-sarcoglycan-deficient) patients is performed. Two cohorts undergo gene transfer in a standard three-six dose escalation scheme to establish maximum tolerated dose (MTD) using toxicity. A minimum of three subjects are enrolled into each cohort. The first cohort receives a total dose of 3×10¹³ vg split between the two extremities (1.5×10¹³ vg per limb). The vector is infused through the femoral artery using a percutaneous balloon catheter. This is a one-time vector infusion. The second cohort receives 1×10¹⁴ vg total dose—split between the two quads (5×10¹³ vg per limb) delivered to the quadriceps muscles according to the same protocol. All patients undergo a muscle biopsy at 3 months (one leg), and 6 months (contra lateral leg) post-gene therapy.

More specifically, patients receive general anesthesia during the procedure. Procedures are performed under sterile conditions. The femoral arteries are catheterized percutaneously in the groin. A fluoroscopy guided 5 Fr catheter is advanced to the vessels supplying the quadriceps muscle. A blood pressure cuff at the knee serves as a tourniquet to promote vector delivery to the quadriceps muscles. A balloon catheter prevents backflow of vector to general circulation. Blood flow to the extremity is occluded for 10 minutes to promote transport through the endovascular barrier. Prior to vector administration, a pre-vector flush of saline (2.5 ml/kg) is given over one minute, immediately followed by occluding blood flow to the extremity. AAVrh.74.tMCK.hSGCA is infused over 60 seconds at a dose of 1.5×10¹³ vg per limb in 2.5 ml/kg of Tris buffered saline for the low-dose cohort, and 5×10¹³ vg per limb in 2.5 ml/kg of Tris buffered saline for the higher dose cohort. The extremity remains isolated from the circulation for 10 minutes before releasing the tourniquet A post-vector flush (2.5 ml/kg) is infused over one minute prior to release of tourniquets. Direct pressure is applied for 10 minutes to ensure hemostasis.

Patients undergo muscle biopsies at two time points, three and six months (on contralateral limbs). Biopsy evaluation includes analysis of alpha-sarcoglycan expression and the entire sarcoglycan complex by immune stains and western blots. Mononuclear cells (CD4+ and CD8+, macrophages) are assessed as is MHC I and II expression. On a monthly basis, patents are evaluated for neutralizing antibodies to rAAV8 along with ELISpots to both rh.74 capsid and alpha-sarcoglycan protein. Muscle strength of the quadriceps is evaluated by quantitative myometry and timed functional tests of standing from a sitting position and walking 9 meters.

Example 7 Isolated Whole Limb Re-Circulation (IWLRC) Protocol

Some chemotherapeutic agents have been delivered by limb perfusion as described in Justison et al., JECT, 41: 231-234 (2009) and van Akkooi et al., Eur. J. Cardio-thoracic Surgery, 30: 408-410 (2006). It is contemplated herein that recombinant viruses of the invention can also be delivered to a patient via a re-circulating methodology. The methodology provides controlled dwell time for viral uptake, control of perfusion pressure, vascular pH, vascular oxygenation and clearing of plasma/blood containing antibodies and complement from the targeted circulation and tissue. In brief, a limb of a patient is isolated with a tourniquet, an artery and vein of the limb are accessed with angio-catheters and the two catheters are connected via tubing, stopcocks and a pump. Buffered solution is pumped into the artery and blood and serum is collected from the limb into a sterile bag for redelivery upon completion of the procedure. While the limb is perfused with buffered solution, the viral vector is administered.

More specifically, to deliver AAVrh.74.tMCK.hSGCA to a lower limb of a patient for example, the patient is sedated and anesthetized. The inguinal area is prepared and draped in the usual sterile fashion. Appropriately sized angio-catheters are placed via direct cut down and blunt dissection into the femoral artery and vein at a site just distal to the inguinal ligament allowing enough space to place a tourniquet. The tourniquet allows temporary isolation of the lower extremity. Alternatively, it is contemplated that angio-catheters can be placed percutaneously or at distal sites and targeted by fluoroscopy.

To these angio-catheters a sterile 3/16″ (ID) venous line is connected to the venous catheter with a luer lock. The tubing will contain two 3/16″ single luer connectors separated by a three-inch piece of 3/16″ tubing. Each 3/16″ luer connector will have an associated six-inch pigtail and two-way stopcock. This allows for collection of the blood as it is displaced with a Normosol-R (Hospira Inc., Lake Forest, Ill.) solution. The blood will be mixed with 8 ml ACD-A anticoagulant during collection so that imay be returned post-procedure. From the second 3/16″ double luer connector is again be 3/16″ tubing that is placed within one of the roller-heads of a Maqet HL-20 twin roller pump (Maquet, Hirrlingen, Germany). This roller-head serves as the perfusate pump during the experiment Post roller-head the 3/16″ tubing is connected to a Sorin CSC 14 heat exchanger (Sorin Group USA, Inc., Arvada, Colo.) (28 ml prime volume). The CSC 14 allows for temperature regulation of the perfusate throughout the procedure. A two-inch piece of 3/16″ tubing is connected to the outlet of the CSC 14 heat exchanger where a 3/16″ single luer connector and associated six-inch pigtail and stopcock are connected. A two-inch piece of 3/16″ tubing is connected to the opposite end of the 3/16″ single luer and is then stepped down to ⅛″ (ID) tubing that serves as the return line. The return line is connected to the catheter within the artery with a luer connection. All components are primed with Normosol-R in a sterile manner, and warmed to 37 degrees Celsius prior to connection with the arterial and venous catheters by recirculating through a bag of Normosol-R. The total prime volume of all components is 62 mL+/−10 mL.

Once connected to the venous and arterial cannulas, a tubing clamp is placed between the two 3/16″ luer connectors on the venous limb. Normosol-R is injected into the distal luer connector utilizing a 60 mL syringe, displacing the blood into a 60 mL syringe (containing 8 mL ACD-A) attached to the proximal 3/16″ luer. This process is repeated until the drainage (blood+Normosol) have an immeasurable hematocrit (<6 g/dL). The tubing clamp is removed and limb perfusion with AAVrh.74.tMCK.hSGCA begins. During limb perfusion, venous (drain) pressure is monitored utilizing a disposable pressure transducer connected to the HL-20 pump and to one of the 3/16″ luer connectors within the venous line. The pressure is not allowed to be less than −50 mmHg. To insure the pressure does not go more negative than this, servo regulation of the pump is set to −50 mmHg. As the pressure approaches this pressure, the roller-head automatically slows or stops preventing damage to the vessel. Arterial (return) pressure monitoring is completed in the same manner on the 3/16″ luer connector on the return line. This servo regulation is set to 200 mmHg. The perfusion flow rate is set at 50 mL/min and maintained for one hour.

At the conclusion of one hour of re-circulation, the blood and Normosol-R initially withdrawn during the connection process will be returned. To achieve this, a tubing clamp is placed between the two 3/16″ luer connectors on the venous limb. An empty 60 mL syringe is connected to the proximal luer connector. The 60 mL syringes collected earlier are connected and injected via the distal luer connector in reverse order of their collection. Once the blood has been returned, the circuit is disconnected from the luer connectors and disposed of as biohazard waste. The tourniquet is removed slowly to allow systemic circulation to the limb and the cannulae removed. Pressure is used to control bleeding at the cut down site. Following the procedure, the patient is recovered in an appropriately warmed environment.

Example 8 IWLRC in the Non-Human Primate with a Reporter Construct

IWLRC with AAVrh.74 and a reporter transgene construct comprising a cytomegalovirus promoter and eGFP (AAVrh.74.CMV.eGFP) demonstrates efficiently expressed transgene with broad distribution throughout the major muscles of the lower limb.

Two vector/transgene doses, high 6×10¹² vg/kg and low 2×10¹² vg/kg, were administered to the lower extremities of two rhesus macaques, such that one animal received the low dose to both lower limbs and the other animal received the high dose to both lower limbs. Results achieved with the doses are presented in FIGS. 7 and 8, respectively.

On analysis of the major muscles of the lower extremity, both doses show broad transgene expression throughout the lower extremity with broader and more efficient expression in the lower extremity of the higher dosed animal. At the dose of 6×10¹², IWLRC resulted in greater than 40% muscle fiber transgene expression in major muscles of the lower extremity except the biceps femoris (HBF) and gracilis (HGras) of the Hamstring muscle group. Included in the graphs but not specifically targeted in this protocol as part of the lower limb are the Gluteus (max and med) muscles; broad expression in the gluteus medius and less in the gluteus maximus is noted.

Example 9 IWLRC in the Non-Human Primate with Therapeutic Transgenes

IWLRC was performed in non-human primates usingAAVrh.74 to deliver a therapeutic micro-dystrophin transgene or a therapeutic alpha-sarcoglycan transgene (specifically using AAVrh.74.tMCK.hSGCA). Results achieved with the transgenes are presented in FIGS. 9 and 10, respectively.

The transgenes were expressed with broad distribution throughout the major muscles of the lower limb.

Example 10 Vascular Delivery of AAVrh.74.tMCK.hSGCA to Alpha-Sarcoglycan Knock-Out Mice

A two-dose escalation study was performed in alpha-sarcoglycan knock-out mice. The two doses were 6×10¹¹ vg/kg (low) and 2×10¹² vg/kg (high). The femoral artery of mice was catheterized and AAV74.tMCK.hSGCA was delivered at high or low dose in 100 μl. A tourniquet placed mid-thigh contained vector delivery to the lower extremity, limiting delivery to the lower limb muscles. Three months post-gene transfer, lower limb muscles were harvested and assessed for resistance to eccentric contraction based injury and tetanic force.

Efficacy was demonstrated at both high and low dose. There was significant improvement versus alpha-sarcoglycan knock-out controls at both high and low dose. The high dose was not significantly different than wild-type mice (ANOVA). See FIG. 11.

While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the claims should be placed on the invention.

All documents referred to in this application are hereby incorporated by reference in their entirety. 

1.-23. (canceled)
 24. A recombinant AAV vector comprising a polynucleotide encoding alpha-sarcoglycan, wherein the polynucleotide comprises a nucleotide sequence at least 95% identical to SEQ ID NO:
 3. 25. The recombinant AAV vector of claim 24, wherein the polynucleotide sequence encoding alpha-sarcoglycan comprises the nucleotide sequence set forth in SEQ ID NO:
 3. 26. The recombinant AAV vector of claim 24, wherein the vector is of the serotype AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11 or AAV rh.74.
 27. The recombinant AAV vector of claim 26, wherein the vector is of the serotype AAV rh.74.
 28. The recombinant AAV vector of claim 24, wherein the polynucleotide sequence is operably linked to a muscle-specific control element.
 29. The recombinant AAV vector of claim 28, wherein the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor (MEF) element, muscle creatine kinase (MCK) promoter, truncated MCK (tMCK) promoter, myosin heavy chain (MHC) control element, MHCK7 promoter, C5-12, murine creatine kinase enhancer element, skeletal fast-twitch troponin c gene element, slow-twitch cardiac troponin c gene element, slow-twitch troponin gene element, hypoxia response element (HRE), steroid-inducible element or glucocorticoid response element (GRE).
 30. The recombinant AAV vector of claim 29, wherein the muscle-specific control element is the truncated MCK (tMCK) promoter.
 31. The recombinant AAV vector of claim 24, wherein the vector comprises a AAV rh.74 capsid that comprises a sequence that is at least 95% identical to SEQ ID NO:
 2. 32. The recombinant AAV vector of claim 24, wherein the AAV rh.74 capsid comprises the sequence of SEQ ID NO:
 2. 33. A composition comprising the recombinant AAV vector of claim 24 and a pharmaceutically acceptable carrier, diluent or adjuvant.
 34. A method of improving muscle function in a patient afflicted with limb girdle muscular dystrophy type 2D (LGMD 2D) comprising administering to the patient, a therapeutically effective amount of the recombinant AAV vector of claim
 24. 35. A method of treating muscular dystrophy in a patient in need thereof comprising administering to the patient, a therapeutically effective amount of the recombinant AAV vector of claim
 24. 36. The method of claim 35, wherein the muscular dystrophy is limb girdle muscular dystrophy type 2D (LGMD 2D). 